GLP-1 agonists like Ozempic reduce the risk of dementia in type 2 diabetes patients. The research followed over 88,000 individuals for up to ten years, showing a 30% lower risk compared to sulfonylureas and a 23% lower risk compared to DPP-4 inhibitors. These findings can guide doctors in selecting medications for older diabetes patients. However, further randomized trials are needed to confirm these results.
GLP-1 agonists like Ozempic reduce the risk of dementia in type 2 diabetes patients. The research followed over 88,000 individuals for up to ten years, showing a 30% lower risk compared to sulfonylureas and a 23% lower risk compared to DPP-4 inhibitors. These findings can guide doctors in selecting medications for older diabetes patients. However, further randomized trials are needed to confirm these results.
Share this Article
Recommended